Page 2 - Edith Sanchez News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Working with all manufacturers to make sure there is a supply of infant formula. >> reporter: but parents say they need a better solution right now. >> it's not something that a parent should have to deal with. >> reporter: elizabeth cohen, cnn, reporting. it is an incredible struggle. here is dr. edith sanchez with her very cute 7-month-old who is excited to be with us too. >> so excited, it's good to see you. >> i love this, wonderful. i love that william is all gums. look, i mean, you can relate, right, as a mom to a 7-month-old, the kind of struggle that so many families are now dealing ...

Their eyes, they have light colored stools or dark colored urine, that's a sign that they may have hepatitis. you should be reaching out before your child develops those signs, you should be reaching out with early concerns. and again, this remains rare, but we're all educating ourselves. >> all right. thank you so much for imparting your advice to us and inviting and educating all of us about very tough topics. dr. sanchez, our thanks to little william there too, he did great. >> thank you. coming up, the siege of the steel plant in mariupol, ukraine, continues. ukrainian officials say they...

Edith Sanchez looks forward to returning home for Mother's Day after undergoing a fetoscopic procedure to repair her son's spina bifida before birth.

For very young children. the fda experts were supposed to meet tomorrow to discuss pfizer's proposal to vaccinate children ages 6 month through 5 years. but that meeting postponed for about two months. >> there was additional data that was submitted to the fda late last week, on thursday and friday, that changed the fda's perception of the absolute efficacy of the vaccine. >> let's get insights from dr. edith sanchez, a pediatrician. grateful for your time. i'm putting up for our viewers to see what happened. they are waiting for three-dose data from the clinical study to be available in early...

And as a pediatrician, this is, of course, frustrating. but i think warranted. i think it's the best we know that happened here and everything we know, we know from press releases. none of us have seen the data. but what we know is that two doses may not have been enough to induce the immune response we're hoping to get in this age group. the efficacy is really what's at stake here and what we're hoping to gather more data on with this potential third dose. the safety, however, this is important to remember, the safety data is there and it's sound. it's safe. what we're waiting for is a potent...